Taimei Technology (02576.HK)?is a leading AI-powered drug clinical development platform, serving the pharmaceutical R&D, pharmacovigilance, and marketing sectors. Guided by the core philosophy of?AI for Success, Taimei combines full-stack AI capabilities with over a decade of deep domain expertise in drug clinical development. The company has developed a proprietary vertical-specific large language model integrated with dynamic learning algorithms, giving rise to the?"Wensi" AI Platform. This platform delivers trusted, usable, and perceivable AI agents and end-to-end AI-powered solutions to customers worldwide, empowering high-quality industry development and enabling faster, more successful new drug development. Headquartered in China with a global vision, Taimei Technology operates branch offices in the United States and Singapore. The company has provided digital and intelligent solutions to over 1,600 pharmaceutical companies and CROs, with users across more than 30 countries and regions, while maintaining a leading market share for its core products in China.